Background : The NOVEOS® method is a chemiluminescent immunoassay used to provide quantitative detection of total IgE and allergen-specific IgE antibodies in human serum. The IgE antibody assay has an essential place in the diagnosis of mediated IgE allergies. This system could become an alternative to the techniques used today. NOVEOS® uses a quick and convenient method to give results concerning the patient's sensitization profile towards allergens. The volume required for the assays is 4 μl (against more than 100 μl for current techniques), which is particularly important in pediatric and geriatric populations where it may be more difficult to take larger samples. NOVEOS® also brings true autonomy. In fact, the incorporated reagents provide sufficient capacity for 8 hours of continuous testing. Objective: Validate the NOVEOS® system as an allergy diagnostic tool, by estimating the sensitivity and specificity of the NOVEOS® assays compared to the gold standard diagnostic represented by the clinical history and PT positive, for a panel of 20 allergens Methods: This is a validation study of a new immunoassay method (Système NOVEOS®). The study includes : * A preliminary phase to familiarize the team with the use of the NOVEOS® system. It is planned to analyze its technical characteristics: the precision, the sensitivity. Eight allergens will be tested, on a cohort of 136 patients * A validation study of the technique as a diagnostic tool for allergy (sensitivity and specificity compared to the gold standard represented by clinical history and positive PT) and comparison between the new technique and the ImmunoCap® system. Twenty allergens will be tested prospectively, each on 50 cases and 10 controls. A single patient may be both a case for an allergen and a witness for another. For rare allergies, the blood database of the Allergy Service will be used, and affected patients will be contacted to request their non-opposition.
Study Type
OBSERVATIONAL
Enrollment
536
The NOVEOS® System is a fully automated, high-throughput immunoassay platform that uses magnetic microbeads as a solid phase. This is a partially closed system that is primarily intended for the determination of specific IgE with NOVEOS® Hycor allergens. It has the CE mark.
University Hospital of Montpellier
Montpellier, Occitanie, France
Sensitivity and specificity of the NOVEOS® assay compared to the gold standard diagnosis.
In order to validate the NOVEOS® system as an allergy diagnostic tool, We have to estimate the sensitivity and specificity of the NOVEOS® assays compared to the gold standard diagnostic represented by the clinical history and Prick Test positive, for a panel of 20 allergens.
Time frame: 24 months
Specific IgE assessed by NOVEOS®
The serum-specific IgE assay is an in vitro assay of IgE antibodies that are able to bind specifically to their allergen. Today, there are techniques that allow the assay of both the IgE reactivity against sources of allergens, but also against the different allergenic components. The results of the NOVEOS® method will be considered acceptable according to the following criteria: * Total agreement ratio of sample recovery ≥ 0.8 * Linear Regression / Correlation between the 2 techniques, R ≥ 0.8
Time frame: 24 months
Specific IgE assessed by Thermo-Fisher ImmunoCAP®
The serum-specific IgE assay is an in vitro assay of IgE antibodies that are able to bind specifically to their allergen. Today, there are techniques that allow the assay of both the IgE reactivity against sources of allergens, but also against the different allergenic components. There are already commercially available, validated and standardized methods; the most used is the Thermo-Fisher ImmunoCAP® (capable of detecting specific IgE amounts\> 0.1 kUA / L).
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.